Amie Hornaman

Dr. Amie Hornaman is a practitioner focusing on thyroid dysfunction and Hashimoto's disease. Her work addresses thyroid hormone regulation, including T3, T4, and reverse T3, alongside the impacts of stress, viral triggers, and lifestyle factors on thyroid health. She also discusses diagnostic lab testing and treatment approaches for thyroid disorders.

15 claims checked on air: 2 context 2 contradicted 5 overstated 4 supported 2 unverified

What they said on air - contradicted

0:34:10contradictedhighWhat Doctors Don't Tell You About Your Thyroid | Dr. Amie Ho

Eighty to ninety percent of the population has Hashimoto's thyroiditis.

"I think it's safe to say like 80 to 90% of the population has Hashi." (said at 0:34:10)

The speaker's claim that 80% to 90% of the population has Hashimoto's thyroiditis is contradicted by epidemiological evidence. A comprehensive global systematic review and meta-analysis of 48 studies covering over 22 million participants found that the overall adult prevalence of Hashimoto's thyroiditis is approximately 7.5% (95% CI: 5.7% to 9.6%), with regional estimates ranging from 5.8% to 14.2%. Even when considering thyroid autoantibody seroprevalence in general populations, figures remain far below the claimed 80% to 90%.

contradicts: Global prevalence and epidemiological trends of Hashimoto's thyroiditis in adults: A syste… (Frontiers in public health 2022) · cited 267x in the literature
"A total of 11,399 studies were retrieved, of which 48 met the research criteria... Furthermore, there are two projects involving 19 countries and 22,680,155 participants. The prevalence of Hashimoto's thyroiditis was 7.5 (95%CI 5.7-9.6%), while in the low-middle-income group the prevalence was 11.4 (95%CI 2.5-25.2%)." (abstract, results)
pubmed full study (doi)

0:47:18contradictedlowWhat Doctors Don't Tell You About Your Thyroid | Dr. Amie Ho

Hypothyroidism or low thyroid function impairs the effectiveness of GLP-1 receptor agonist medications.

"Thyroid's low and slow, GLP-1 won't work. People are wasting money." (said at 0:47:18)

Clinical evidence directly contradicts the claim that hypothyroidism prevents GLP-1 receptor agonists from working. In a retrospective case-control study evaluating weight loss with the GLP-1 receptor agonist liraglutide, individuals with hypothyroidism on stable levothyroxine therapy achieved significant and comparable weight loss relative to matched controls without thyroid disease (-10.8% vs. -8.9%, P = 0.940), with similar proportions reaching ≥5% total body weight loss (79.2% vs. 71.0%, P = 0.248). Baseline TSH levels within the normal reference range did not predict or limit weight loss outcomes.

contradicts: Weight and body composition outcomes with liraglutide in individuals with well-treated hyp… (PloS one 2025) · cited 3x in the literature
"Liraglutide leads to clinically meaningful and comparable weight loss in individuals with well-treated hypothyroidism and those without thyroid disease. Body composition changes were also similar between groups." (abstract, conclusions, passage verified)
pubmed full study (doi)

Fact-checked episodes

What Doctors Don't Tell You About Your Thyroid | Dr. Amie HornamanDr. Tyna Moore · as guest

Publications

No PubMed publication profile has been built for this speaker yet.